Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28678694 | 0.73 | PARP1 (0.63) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL93066 | 0.72 | SLC6A4 (0.41) | DRD4 | |
| SCHEMBL13927875 | 0.71 | PARP1 (0.58) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL532134 | 0.70 | PARP1 (1.00) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL28693938 | 0.70 | PARP1 (0.72) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL554735 | 0.70 | PARP1 (0.72) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL351961 | 0.70 | PARP1 (0.72) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL12776191 | 0.70 | PARP1 (0.71) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL2120689 | 0.70 | PARP1 (0.65) | PARP1NR3C2DRD4DRD2MMP12 | |
| SCHEMBL11006154 | 0.69 | PARP1 (0.70) | PARP1NR3C2DRD4DRD2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | PARP1 3253/4885NR3C2 24/4885DRD4 532/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | PARP1 3253/4885NR3C2 24/4885DRD4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.